Amended Current Report Filing (8-k/a)
October 06 2022 - 05:01PM
Edgar (US Regulatory)
0000890821 true 0000890821 2022-09-20
2022-09-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
September 20, 2022
Date
of Report (Date of earliest event reported)
Enveric Biosciences, Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
001-38286 |
|
95-4484725 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
Enveric Biosciences, Inc.
4851 Tamiami Trail N,
Suite 200
Naples,
FL
34103
(Address of principal executive offices) (Zip code)
Registrant’s
telephone number, including area code:
(239)
302-1707
N/A
(Former name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common stock, par value $0.01 per share |
|
ENVB |
|
The Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
4.01 Changes in Registrant’s Certifying Accountant.
This
Current Report on Form 8-K/A is being filed solely to amend the
Current Report on Form 8-K filed by Enveric Biosciences, Inc. (the
“Company”) on September 23, 2022 (the “Original Report”) to add as
Exhibit 16.1 the letter received on October 6, 2022 from the
Company’s former independent registered public accounting firm,
Friedman LLP, regarding the disclosure made in the Original
Report.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Date:
October 6, 2022 |
ENVERIC
BIOSCIENCES, INC. |
| |
|
|
|
By: |
/s/
Joseph Tucker |
| |
|
Joseph
Tucker |
| |
|
Chief
Executive Officer |
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Feb 2023 to Mar 2023
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Mar 2022 to Mar 2023
